Weave Bio
Weave Bio is an AI-native life sciences company founded in 2022, headquartered in San Francisco, California, with additional operations in New Haven, Connecticut. The company focuses on regulatory automation and lifecycle management for drug development, offering a cloud-based platform designed to streamline the preparation of regulatory dossiers from preclinical to postmarket stages. Weave Bio has raised approximately $36 million in funding, including a $20 million Series A round in late 2025. The flagship product, the Weave Platform, serves as an end-to-end regulatory workbench that supports the entire regulatory content lifecycle. Key features include AI-powered authoring, a specialized tool for Investigational New Drug (IND) application preparation, and compliance with global regulatory standards. Weave Bio aims to enhance the efficiency and quality of regulatory processes, helping pharmaceutical companies, biotech firms, contract research organizations, and regulatory consultants navigate complex requirements. The company is expanding its reach beyond the U.S. into Europe, Japan, and Latin America.